Diagnostic potential of total serum ghrelin in autoimmune gastritis: A systematic review and meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 41818289.
- Also identified by DOI 10.1371/journal.pone.0344129 and PMC identifier 12981498.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Autoimmune gastritis (AIG) is a chronic inflammatory condition characterized by the destruction of gastric parietal cells. The invasive nature of diagnostic procedures and risk of confounding factors hinder the development of reliable diagnostic tools for AIG. We conducted a systematic search of four databases. After assessing the study quality using the ROBINS-E tool, a meta-analysis was performed using a random-effects model. Meta-regression and sensitivity analyses were conducted to explore the sources of heterogeneity and impact of study bias. The pooled mean difference in total serum ghrelin (pmol/L) between patients with AIG and healthy controls was -65.28 (95% CI: -178.54, 47.97). Subgroup analysis showed that the mean differences in serum ghrelin for mild, moderate, and severe atrophy were -78.85 (95% CI: -165.17, to 7.48), -91.97 (95% CI: -183.11, to -0.84), and -110.67 (95% CI: -204.77, to -16.56), respectively. The sensitivity analysis confirmed that the exclusion of studies with high-risk bias did not significantly alter the results. Meta-regression indicated that BMI contributed substantially to heterogeneity. Although total serum ghrelin levels were not significantly different between patients with AIG and healthy controls, significantly lower levels were observed in patients with moderate-to-severe gastric atrophy. Given the high heterogeneity and limitations of existing studies, the diagnostic utility of serum ghrelin in AIG warrants further investigation.
Medical subject headings
- Ghrelin
- Autoimmune Diseases
- Gastritis